A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients

Francesco Cortiula, Giulia Pasello, Alessandro Follador, Giorgia Nardo, Valentina Polo, Elisa Scquizzato, Alessandro Del Conte, Marta Miorin, Petros Giovanis, Alessandra D'Urso, Salvator Girlando, Giulio Settanni, Vincenzo Picece, Antonello Veccia, Carla Corvaja, Stefano Indraccolo, Giovanna De Maglio

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: circulating tumor DNA (ctDNA) is a source of tumor genetic material for EGFR testing in NSCLC. Real-word data about liquid biopsy (LB) clinical practice are lacking. The aim of the study was to describe the LB practice for EGFR detection in North Eastern Italy.

METHODS: we conducted a multi-regional survey on ctDNA testing practices in lung cancer patients.

RESULTS: Median time from blood collection to plasma separation was 50 min (20-120 min), median time from plasma extraction to ctDNA analysis was 24 h (30 min-5 days) and median turnaround time was 24 h (6 h-5 days). Four hundred and seventy five patients and 654 samples were tested. One hundred and ninety-two patients were tested at diagnosis, with 16% EGFR mutation rate. Among the 283 patients tested at disease progression, 35% were T790M+. Main differences in LB results between 2017 and 2018 were the number of LBs performed for each patient at disease progression (2.88 vs. 1.2, respectively) and the percentage of T790M+ patients (61% vs. 26%).

Original languageEnglish
Article number765
Number of pages7
JournalDiagn.
Volume10
Issue number10
DOIs
Publication statusPublished - Sep 28 2020

Fingerprint Dive into the research topics of 'A Multi-Center, Real-Life Experience on Liquid Biopsy Practice for EGFR Testing in Non-Small Cell Lung Cancer (NSCLC) Patients'. Together they form a unique fingerprint.

Cite this